Quantification of the transporter substrate fexofenadine in cell lysates by liquid chromatography/tandem mass spectrometry
- 18 July 2011
- journal article
- research article
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 25 (16), 2361-2366
- https://doi.org/10.1002/rcm.5111
Abstract
Drug–drug interactions at transporters present a significant and under‐investigated clinical problem. Investigations of specific transporter functions and screening for potential drug‐drug interactions, both in vitro and especially in vivo, will require validated experimental probes. Fexofenadine, an approved, well‐tolerated drug, is a promising probe for studies of membrane transporter function. Although fexofenadine pharmacokinetics are known to be controlled by transporters, the contributions of individual transporters have not been defined. We have developed a rapid, specific, and sensitive analytical method for quantitation of fexofenadine to support this work. This liquid chromatography/tandem mass spectrometry (LC/MS/MS) method quantifies fexofenadine in cell lysates from in vitro studies using cetirizine as the internal standard. Cell lysates were prepared for analysis by acetonitrile precipitation. Analytes were then separated by gradient reversed‐phase chromatography and analyzed by tandem mass spectrometry using the m/z 502.17/466.2 transition for fexofenadine and m/z 389.02/201.1 for cetirizine. The method exhibited a linear dynamic range of 1–500 ng/mL for fexofenadine in cell lysates. The lower limit of quantification was 1 ng/mL with a relative standard deviation of less than 5%. Intra‐ and inter‐day precision and accuracy were within the limits presented in the FDA guidelines for bioanalysis. We also will validate this method to support not only the quantification of fexofenadine, but also other probe drugs for drug–drug interaction studies. This method for quantification will facilitate the use of fexofenadine as a probe drug for characterization of transporter activity. Copyright © 2011 John Wiley & Sons, Ltd.This publication has 13 references indexed in Scilit:
- Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in HumansClinical Pharmacology & Therapeutics, 2007
- CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANSDrug Metabolism and Disposition, 2005
- Determination of fexofenadine in human plasma using 96-well solid phase extraction and HPLC with tandem mass spectrometric detectionJournal of Pharmaceutical and Biomedical Analysis, 2004
- Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detectionJournal of Pharmaceutical and Biomedical Analysis, 2004
- Organic anion‐transporting polypeptide (OATP) transporter family and drug dispositionEuropean Journal of Clinical Investigation, 2003
- Effect of St John's wort on the pharmacokinetics of fexofenadineClinical Pharmacology & Therapeutics, 2002
- Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadineClinical Pharmacology & Therapeutics, 2002
- Determination of fexofenadine in human plasma and urine by liquid chromatography–mass spectrometryJournal of Chromatography B, 2002
- The effect of rifampin administration on the disposition of fexofenadineClinical Pharmacology & Therapeutics, 2001
- OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.1999